Abstract
The emergence of oxidized low-density lipoprotein (OxLDL) is crucial for the progression of cardiovascular diseases (CVD) linked to atherosclerosis. OxLDL stimulates endothelial activation and smooth muscle proliferation and has an atherosclerotic-promoting effect. The measurement of OxLDL correlates with the presence of CVD and may be a prognostic marker for future health outcomes. Circulating OxLDLs can be used as biomarkers since their levels rise in patients with advanced atherosclerosis. Immunological methods have proven to be very useful methodologies. Anti-OxLDL monoclonal antibodies have been developed that bind strongly to OxLDL and are used in ELISA for OxLDL measurements. Routine inclusion of OxLDL estimation in an at-risk population can help the clinicians understand the disease initiation and progression and improve early intervention and management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
